2015 Cell Biology Presentation 
Drug Target Review
NOVEMBER 24, 2023
There is this level of understanding about brains that presently doesn’t exist. 2015 February 5 [2023 October 17]; 9(19)1-3. Lichtman stated: “Connectomics is the only pathway…If we get to a point where doing a whole mouse brain becomes routine, you could think about doing it in, say, animal models of autism. What it is for?
Drug Target Review
NOVEMBER 17, 2023
About the authors Aleta Pupovac Publications Officer, Cartherics Aleta is a cell biologist and immunologist who is passionate about translational science. He was the founding CEO of the Australian Stem Cell Centre. Alan founded the Monash Immunology and Stem Cell Laboratories at Monash University (2004-7).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
APRIL 9, 2024
Our approach to investigate the toxicity driven by nucleolar stress was to induce it with certain arginine-rich peptides, present in patients of ALS, which were known to accumulate at nucleoli and cause this type of stress. However, our study was first to show that inducing nucleolar stress in an adult mammal accelerates aging.
Codon
APRIL 9, 2024
The existing literature written in English on this story tends to attribute Tu Youyou’s achievements to a solo discovery, an understandable consequence of Tu receiving the Nobel Prize in Physiology or Medicine in 2015. Miller and Su published an article on Tu’s story in Cell in 2011. WRAIR had discovered A.
DrugBank
JUNE 27, 2023
” 4 The term originally rose to prominence after the completion of the Human Genome Project 5 as a call to action in the face of wide disparities between treatment outcomes within the same clinical presentation; however, the exact meaning has changed as technology continues to advance. whitehouse.gov [link] (2015). Waeber, G. &
The Pharma Data
OCTOBER 22, 2020
Presented at the ESMO 2019 Congress, the combination of monalizumab and cetuximab demonstrated a manageable safety profile and a response rate of 27.5% (36% and 17% in IO-naïve, n=22, and IO-pretreated patients, n=18, respectively). Additional details on the INTERLINK-1 clinical trial can be found here.
Codon
OCTOBER 22, 2024
Still, shortly after I read Mastroianni’s article, Ben Recht asked on Twitter if there were any articles presenting “a positive case for peer review.” Up to 10 papers were randomly selected and plotted for each year from 1881 to 2015. Each dot corresponds to one research paper.
Expert insights. Personalized for you.
105 
Let's personalize your content